AVADEL PHARMACEUTICALS PLC

Business Segments Avadel Pharmaceuticals plc

Stocks

AVDL

IE00BDGMC594

Pharmaceuticals

Delayed Nasdaq Other stock markets 16:00:00 2026-02-11 EST			5-day change	1st Jan Change
21.64 ^USD	+0.05%		-.--%	+0.42%

05-01	Avadel Pharmaceuticals plc Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-02	Monopar Therapeutics Inc. Appoints Susan Rodriguez as Chief Commercial and Strategy Officer, Effective from March 2, 2026	CI

Sales 2025 by Business Segment

© MarketScreener.com See more

Sales 2025 by Geography

© MarketScreener.com See more

Historical Breakdown of Revenue by Business Segments

Net Income: Breakdown by Business Segment

Breakdown by Business Segment (USD)

Fiscal Period: December	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Pharmaceutical Products
Development and Commercialization of Pharmaceutical Products						-	-	27.96M	169M	279M
Total Assets						247M	133M	165M	164M	285M
Interest Expense						-9.94M	-12.34M	-9.89M	-10.83M	-9.31M
Income Tax Expense						-15.82M	26.02M	-501K	-247K	-1.89M
CAPEX						-26K	-716K	-	-	-562K
EBT						-93.14M	-111M	-161M	-49.08M	62.78M
Gross Profit						-	-	27.12M	154M	263M
D&A						815K	1.49M	1.77M	2.68M	4.01M
Operating Income						-85.55M	-98.56M	-138M	-42.4M	70.21M
Net Income						-77.33M	-137M	-160M	-48.83M	64.67M

Geographical Revenue Distribution History

Geographical breakdown of sales (USD)

Fiscal Period: December	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Ireland						-	-	-	-	-
Total Assets						9.82M	11.3M	11.75M	12.21M	7.67M
United States						-	-	-	-	-
Total Assets						19.6M	19.41M	18.41M	17.51M	18.88M
Total Assets						-	-	-	-	-

Rankings

Rankings

Currency / Forex

Commodities

Cryptocurrencies

Interest Rates

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!

SEIZE THE OFFER!